Followers | 194 |
Posts | 11500 |
Boards Moderated | 2 |
Alias Born | 06/20/2022 |
Thursday, February 29, 2024 10:50:10 AM
Recent NRBO News
- NeuroBo Pharmaceuticals to Participate in Investor Conferences in October • PR Newswire (US) • 10/01/2024 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/30/2024 12:07:00 PM
- NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity • PR Newswire (US) • 09/30/2024 12:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/20/2024 08:20:16 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 09/20/2024 08:15:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/19/2024 08:10:30 PM
- NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference • PR Newswire (US) • 09/03/2024 12:01:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/21/2024 08:02:05 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 09:08:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 12:01:18 PM
- NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update • PR Newswire (US) • 08/14/2024 12:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:01:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 12:30:30 PM
- NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity • PR Newswire (US) • 08/13/2024 12:01:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 08/07/2024 12:00:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 12:30:17 PM
- NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity • PR Newswire (US) • 08/06/2024 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 12:30:18 PM
- NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01 • PR Newswire (US) • 07/30/2024 12:01:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 07/25/2024 04:15:06 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/24/2024 09:11:14 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 07/18/2024 12:21:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/16/2024 12:30:27 PM
- NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity • PR Newswire (US) • 06/26/2024 01:06:00 PM
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • SMX • Oct 3, 2024 7:00 AM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM